Artelo Biosciences Résultats passés
Passé contrôle des critères 0/6
Artelo Biosciences's earnings have been declining at an average annual rate of -23.6%, while the Pharmaceuticals industry saw earnings declining at 0.2% annually.
Informations clés
-23.6%
Taux de croissance des bénéfices
42.3%
Taux de croissance du BPA
| Pharmaceuticals Croissance de l'industrie | 6.0% |
| Taux de croissance des recettes | n/a |
| Rendement des fonds propres | -143.0% |
| Marge nette | n/a |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Pas de mise à jour
Recent updates
Artelo jumps 21% as publication highlights pre-clinical data on drug platform
Aug 16Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
Mar 28
Artelo Biosciences Rounding A Corner With Cannabinoid-Based Therapy
Mar 09Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Nov 02Relief For Cancer Patients In Artelo Bioscience Pipeline
Jul 12Artelo Biosciences (NASDAQ:ARTL) Is In A Good Position To Deliver On Growth Plans
May 20Is Artelo Biosciences (NASDAQ:ARTL) In A Good Position To Invest In Growth?
Feb 04INO, VXRT, BTU and TTM among premarket gainers
Feb 02Artelo Biosciences EPS misses by $0.04
Jan 14Artelo Biosciences on go with cancer appetite recovery study
Nov 16Ventilation des recettes et des dépenses
Comment Artelo Biosciences gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -10 | 4 | 7 |
| 31 Mar 24 | 0 | -10 | 4 | 6 |
| 31 Dec 23 | 0 | -9 | 4 | 6 |
| 30 Sep 23 | 0 | -10 | 5 | 5 |
| 30 Jun 23 | 0 | -9 | 5 | 5 |
| 31 Mar 23 | 0 | -10 | 6 | 5 |
| 31 Dec 22 | 0 | -10 | 6 | 4 |
| 30 Sep 22 | 0 | -13 | 7 | 6 |
| 30 Jun 22 | 0 | -13 | 7 | 6 |
| 31 Mar 22 | 0 | -12 | 6 | 6 |
| 31 Dec 21 | 0 | -12 | 6 | 6 |
| 30 Nov 21 | 0 | -9 | 5 | 4 |
| 31 Aug 21 | 0 | -7 | 5 | 3 |
| 31 May 21 | 0 | -7 | 4 | 2 |
| 28 Feb 21 | 0 | -5 | 3 | 2 |
| 30 Nov 20 | 0 | -5 | 3 | 2 |
| 31 Aug 20 | 0 | -5 | 3 | 2 |
| 31 May 20 | 0 | -4 | 3 | 2 |
| 29 Feb 20 | 0 | -4 | 3 | 2 |
| 30 Nov 19 | 0 | -3 | 2 | 2 |
| 31 Aug 19 | 0 | -2 | 2 | 1 |
| 31 May 19 | 0 | -2 | 2 | 1 |
| 28 Feb 19 | 0 | -2 | 1 | 1 |
| 30 Nov 18 | 0 | -3 | 1 | 1 |
| 31 Aug 18 | 0 | -2 | 1 | 1 |
| 31 May 18 | 0 | -2 | 1 | 1 |
| 28 Feb 18 | 0 | -1 | 1 | 1 |
| 30 Nov 17 | 0 | -1 | 0 | 0 |
| 31 Aug 17 | 0 | 0 | 0 | 0 |
| 31 May 17 | 0 | 0 | 0 | 0 |
| 28 Feb 17 | 0 | 0 | 0 | 0 |
| 30 Nov 16 | 0 | 0 | 0 | 0 |
| 31 Aug 16 | 0 | 0 | 0 | 0 |
| 31 May 16 | 0 | 0 | 0 | 0 |
| 29 Feb 16 | 0 | 0 | 0 | 0 |
| 30 Nov 15 | 0 | 0 | 0 | 0 |
| 31 Aug 15 | 0 | 0 | 0 | 0 |
| 31 May 15 | 0 | 0 | 0 | 0 |
| 28 Feb 15 | 0 | 0 | 0 | 0 |
| 30 Nov 14 | 0 | 0 | 0 | 0 |
Des revenus de qualité: ARTL is currently unprofitable.
Augmentation de la marge bénéficiaire: ARTL is currently unprofitable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: ARTL is unprofitable, and losses have increased over the past 5 years at a rate of 23.6% per year.
Accélération de la croissance: Unable to compare ARTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Bénéfices par rapport au secteur d'activité: ARTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.4%).
Rendement des fonds propres
ROE élevé: ARTL has a negative Return on Equity (-143.01%), as it is currently unprofitable.